期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

半负荷量氯吡格雷反应对氯吡格雷抵抗的预测价值 被引量：3

下载PDF
导出
摘要 目的探讨半负荷量氯吡格雷反应能否预测氯吡格雷抵抗。方法急性冠脉综合征(ACS)患者138例,于服用氯吡格雷150 mg前、服药后12～18 h内及第4天,采血检测10和20μmol/L二磷酸腺苷(ADP)诱导的血小板聚集率。结果分别以10和20μmol/LADP为诱导剂时,半负荷量之后的血小板聚集值不能预测氯吡格雷抵抗(P>0.05);半负荷量之后的血小板聚集降低值小于0.5ohms以及半负荷量之后血小板聚集降低的百分率小于12.22%和16.03%可预测氯吡格雷抵抗(P<0.001)。结论服用半负荷量氯吡格雷150 mg后12～18 h内的血小板聚集值不能预测氯吡格雷抵抗现象;而此值与用药前血小板聚集值的差值以及降低的百分率均可在一定程度上预测氯吡格雷抵抗现象。
作者 李亚 崔炜 刘凡 杨晓红 谷国强 谢瑞芹 鲁静朝 郑红梅 张光明
机构地区 河北工程大学附属医院 河北医科大学第二医院心血管内科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第19期4126-4127,共2页 Chinese Journal of Gerontology
基金 河北省科技厅基金项目(No.06271107D)
关键词 急性冠脉综合征 氯吡格雷 血小板聚集率 预测指标 全血阻抗法
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cyto-chrome P450 3A4 metabolic activity to the phenomenon of clopidogrel re-sistance(J).Circulation,2004;109(2):166-71.
  • 2Gurbel PA,Antonino MJ,Bliden KP,et al.Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutane-ous coronary intervention:a potential antiplatelet therapeutic target(J).Platelets,2008;19(8):595-604.
  • 3Patti G,Nusca A,Mangiacapra F,et al.Point-of-care measurement of clo-pidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO(Anti-platelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)study(J).J Am Coll Cardiol,2008;52(14):1128-33.
  • 4Dyszkiewicz-Korpanty A,Olteanu H,Frenkel EP,et al.Clopidogrel anti-platelet effect:an evaluation by optical aggregometry,impedance aggre-gometry,and the platelet function analyzer(PFA-100)(J).Platelets,2007;18(7):491-6.
  • 5Gachet C.ADP receptors of platelets and their inhibition(J).Thromb Haemost,2001;86(1):222-32.
  • 6Sibbing D,Braun S,Morath T,et al.Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis(J).J Am Coll Cardiol,2009;53(10):849-56.

同被引文献27

  • 1Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009,361 : 1045-1057.
  • 2Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel inpatients with a planned invasive strategy for acute coronary syndromes (PLATO):a Randomised double blind study. Lancet,2010,375:283-293.
  • 3Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost, 2011,105 : S75-81.
  • 4Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability,and initial efficacy of AZD6140, the first reversible oraladenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol,2007,50:1844-1851.
  • 5Azmoon S, Angiolillo DJ. Switching antiplatelet regimens: ahernatives to clopidogrel in patients with acute coronary syndrome undergoing PCI : a review of the literature and practical considerations for the interventional cardiologist [J]. Catheter Cardiovasc Interv, 2013, 81 (2) : 232 -242.
  • 6Benjamin MM, Filardo G, Donsky MS, et al. A pilot study of prasugrel followed by post - procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention [ J ]. J Interv Cardiol, 2013, 26 (1): 38-42.
  • 7DeFelice F, Fiorilli R, Parma A, et al. One-year clinical outcome of patients treated with or without abciximab in rescue coronary angioplasty [J]. IntJ Cardiol, 2013, 163 (3): 294-298.
  • 8Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre - treatment is associated with an increased ischemie risk during elective percutaneous coronary intervention [J]. J Am Coll Cardiol, 2013, 61 ( 1 ) : 23 - 34.
  • 9Loh JP, Pendyala LK, Kitabata H, et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention [J]. AmJCardiol, 2013, 111 (6): 841 -845.
  • 10鲁胜.氯吡格雷在抗血小板治疗中的临床应用[J].医学综述,2008,14(16):2505-2508. 被引量：5

引证文献3

二级引证文献34

中国老年学杂志
2012年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部